An agonist mixture for activating a fast mucokinetic pathway is provided. An example method includes selecting agents for activating the complete mucokinetic pathway, determining proportions of the selected agents for activating the complete mucokinetic pathway in a mixture containing the selected agents, and administering the mixture to a user from a vaporizer, an inhaler, a mister, an e-cigarette, a sprayer, an atomizer, or a pressurized can. The method may further include administering to the user a mixture to be inhaled for nicotine withdrawal.

An agonist mixture for activating a fast mucokinetic pathway is provided. An example method includes selecting agents for activating the complete mucokinetic pathway, determining proportions of the selected agents for activating the complete mucokinetic pathway in a mixture containing the selected agents, and administering the mixture to a user from a vaporizer, an inhaler, a mister, an e-cigarette, a sprayer, an atomizer, or a pressurized can. The method may further include administering to the user a mixture to be inhaled for nicotine withdrawal.

An agonist mixture for activating a fast mucokinetic pathway is provided. An example method includes selecting agents for activating the complete mucokinetic pathway, determining proportions of the selected agents for activating the complete mucokinetic pathway in a mixture containing the selected agents, and administering the mixture to a user from a vaporizer, an inhaler, a mister, an e-cigarette, a sprayer, an atomizer, or a pressurized can. The method may further include administering to the user a mixture to be inhaled for nicotine withdrawal.

This invention relates to a topical herbal formulation that is particularly suitable for the treatment of wounds and a process for the manufacture thereof. More specifically, this invention relates to a topical wound-healing herbal formulation comprising gotu kola (Centella asiatica), greater plantain (Plantago major), figwort (Scrophularia nodosa), yarrow (Achillea millefolium) and Pau d'Arco (Tabebuia impetiginosa). The herbal formulation has both anti-inflammatory and anti-microbial properties. The formulation is particularly effective in the treatment of horse wounds, preventing the formation or raised hairless scars and promoting hair regrowth in the horse without the need for the introduction of an extracellular matrix. The formulation is also suitable for the treatment of general skin disorders in humans including, but not limited to, eczema and nappy rash.

This invention relates to a topical herbal formulation that is particularly suitable for the treatment of wounds and a process for the manufacture thereof. More specifically, this invention relates to a topical wound-healing herbal formulation comprising gotu kola (Centella asiatica), greater plantain (Plantago major), figwort (Scrophularia nodosa), yarrow (Achillea millefolium) and Pau d'Arco (Tabebuia impetiginosa). The herbal formulation has both anti-inflammatory and anti-microbial properties. The formulation is particularly effective in the treatment of horse wounds, preventing the formation or raised hairless scars and promoting hair regrowth in the horse without the need for the introduction of an extracellular matrix. The formulation is also suitable for the treatment of general skin disorders in humans including, but not limited to, eczema and nappy rash.

The invention relates to a composition containing a Withania somnifera extract, obtained by fermentation by incubating the Withania somnifera extract with a filamentous fungus of the Beauveria genus. The composition can be used to treat or prevent -synucleinopathies in a subject.

The invention relates to a composition containing a Withania somnifera extract, obtained by fermentation by incubating the Withania somnifera extract with a filamentous fungus of the Beauveria genus. The composition can be used to treat or prevent -synucleinopathies in a subject.

The invention relates to a composition containing a Withania somnifera extract, obtained by fermentation by incubating the Withania somnifera extract with a filamentous fungus of the Beauveria genus. The composition can be used to treat or prevent -synucleinopathies in a subject.

The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.

The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.